Last updated: September 3, 2026
Ferric derisomaltose is an intravenous iron product marketed in the United States as Monoferric and in Europe and other markets as Monofer. Pharmacosmos is the originator and principal commercial holder. The product competes with ferric carboxymaltose, ferumoxytol, iron sucrose, and low-molecular-weight iron dextran.
The commercial thesis is based on high-dose intravenous administration, reduced infusion frequency, and demand from patients who do not respond adequately to oral iron. The main constraints are hospital formulary control, payer negotiations, established generic intravenous irons, and competitive products with broader indications or stronger contracting positions.
Public filings do not provide a separately reported global revenue figure for ferric derisomaltose. Pharmacosmos is privately held, and product-level sales are not disclosed in the company’s public materials. Financial analysis therefore depends on market access, prescription and procedure data, geographic uptake, and the competitive position of Pharmacosmos’s broader iron portfolio.
What is ferric derisomaltose and how is it used?
Ferric derisomaltose is an intravenous iron replacement therapy consisting of an iron-carbohydrate complex. It is designed to deliver a large iron dose in a single administration while limiting the release of unbound iron.
In the United States, Monoferric is approved for adults with iron deficiency anemia who:
- Have intolerance or an unsatisfactory response to oral iron; or
- Have non-dialysis-dependent chronic kidney disease.
The FDA-approved dosing is:
| Patient weight |
Recommended dose |
| 50 kg or more |
1,000 mg by intravenous infusion |
| Less than 50 kg |
20 mg/kg by intravenous infusion |
The infusion is administered over at least 20 minutes. A second dose may be given when additional iron replacement is clinically required. The U.S. label includes a warning for serious hypersensitivity reactions and recommends monitoring patients during and after administration. (U.S. Food and Drug Administration, 2020)
In Europe, Monofer is used across a broader set of iron-deficiency conditions, subject to country-specific labeling and reimbursement rules. European use includes iron deficiency with or without anemia, chronic kidney disease, heart failure, inflammatory bowel disease, and other settings where oral iron is inadequate or unsuitable.
When did ferric derisomaltose receive FDA approval?
The FDA approved Monoferric on January 14, 2020. The approval was based on clinical studies comparing ferric derisomaltose with iron sucrose and ferric carboxymaltose in adults with iron deficiency anemia.
The U.S. regulatory timeline is:
| Event |
Date |
| FDA approval of Monoferric |
January 14, 2020 |
| U.S. launch |
2020 |
| Initial U.S. indication |
Adults with iron deficiency anemia and oral-iron intolerance or inadequate response; non-dialysis-dependent CKD |
| Administration |
Intravenous infusion, generally 1,000 mg for patients weighing at least 50 kg |
| Regulatory pathway |
New drug application |
| Product status |
Prescription drug |
Ferric derisomaltose was previously marketed in Europe as Monofer. European commercialization gave Pharmacosmos clinical, manufacturing, and market-access experience before the U.S. launch.
How does ferric derisomaltose compare with competing intravenous iron drugs?
Ferric derisomaltose competes mainly on dose size, infusion time, iron utilization, hypophosphatemia risk, and payer cost.
| Product |
Active iron form |
Typical administration |
Principal commercial position |
| Monoferric / Monofer |
Ferric derisomaltose |
Often 1,000 mg in one infusion |
High-dose replacement with low administration frequency |
| Injectafer |
Ferric carboxymaltose |
One or two large doses |
Strong U.S. presence; broad commercial adoption |
| Feraheme |
Ferumoxytol |
Two 510 mg doses or comparable schedule |
Established use in iron deficiency anemia and CKD |
| Venofer |
Iron sucrose |
Multiple lower-dose administrations |
Long-established, widely used, and often lower-cost |
| Infed |
Low-molecular-weight iron dextran |
Total-dose or divided administration |
Flexible dosing, with longstanding clinical familiarity |
Ferric derisomaltose versus ferric carboxymaltose
Ferric carboxymaltose, marketed as Injectafer by American Regent, is the closest branded competitor in high-dose intravenous iron. Both products can reduce the number of visits compared with iron sucrose.
The key clinical and commercial distinction is serum phosphate. Ferric carboxymaltose has a recognized risk of hypophosphatemia, including symptomatic or prolonged cases. Ferric derisomaltose has generally shown a lower incidence of clinically significant hypophosphatemia in comparative studies, although the products are not risk-free. (Wolf et al., 2020)
Injectafer has historically had greater U.S. commercial scale and a broader prescriber base. Monoferric’s opportunity is to convert patients and institutions where phosphate concerns, administration burden, or total treatment cost favor ferric derisomaltose.
Ferric derisomaltose versus iron sucrose
Iron sucrose is a major price and formulary competitor. Its clinical use is entrenched in nephrology, dialysis, hospitals, and outpatient infusion centers. The usual disadvantage is the need for multiple administrations to deliver a full replacement dose.
Monoferric can generate economic value when fewer visits, nursing time, chair time, and transportation costs offset its higher acquisition price. That value is less compelling when a hospital or health system prioritizes unit price over total treatment cost.
Ferric derisomaltose versus ferumoxytol
Feraheme has an established position in adult iron deficiency anemia and in patients with chronic kidney disease. Ferumoxytol uses a two-dose regimen and carries a boxed warning for serious hypersensitivity reactions, including anaphylaxis. Monoferric’s single high-dose administration can be commercially attractive, but Feraheme benefits from physician familiarity and existing payer contracts.
What is the market size and growth outlook for intravenous iron?
The intravenous iron market is supported by several structural factors:
- Oral iron frequently produces gastrointestinal intolerance or inadequate hematologic response.
- Chronic kidney disease increases the need for parenteral iron, particularly in patients receiving erythropoiesis-stimulating agents.
- Heart failure guidelines increasingly recognize iron deficiency as a clinically relevant treatment target.
- Outpatient infusion centers can administer large replacement doses during one visit.
- Hospitals seek to reduce treatment episodes and administration costs.
The market is divided between mature low-cost products and branded high-dose products. Unit growth is likely to be driven by increased diagnosis and treatment of iron deficiency, while revenue growth depends on the share captured by branded formulations and reimbursement levels.
The most attractive segments for ferric derisomaltose are:
| Segment |
Commercial rationale |
| Non-dialysis CKD |
FDA-labeled U.S. use and recurring treatment need |
| Heart failure |
Strong evidence base for intravenous iron, although U.S. labeling may not cover all uses |
| Gastrointestinal disease |
Oral iron may be poorly tolerated or ineffective |
| Women’s health |
Heavy menstrual bleeding and postpartum iron deficiency create high treatment volume |
| Oncology and chronic inflammation |
Oral absorption and utilization can be impaired |
| Hospital outpatient infusion |
Lower frequency can improve operational economics |
Dialysis remains a difficult segment because iron sucrose and other established products are deeply integrated into dialysis-provider protocols. Ferric derisomaltose is more commercially exposed to non-dialysis and specialty-care settings than to the core dialysis market.
What is the financial trajectory of ferric derisomaltose?
Monoferric’s financial trajectory has four phases.
2020 to 2021: U.S. launch and restricted adoption
The product entered the U.S. market during the COVID-19 period, when elective procedures, outpatient visits, and infusion-center activity were disrupted. The launch required formulary placement against Injectafer, Feraheme, and low-cost iron sucrose.
Initial uptake depended on clinical differentiation and the ability of Pharmacosmos to obtain payer coverage. The single-dose regimen provided a clear operational message, but hospitals remained sensitive to acquisition cost.
2022 to 2024: broader commercial penetration
Growth prospects improved as outpatient care normalized and health systems focused on reducing infusion episodes. Comparative evidence on hypophosphatemia created a stronger selling point against ferric carboxymaltose.
The main sources of revenue expansion were:
- New formulary wins;
- Greater use in non-dialysis CKD;
- Conversion from multi-dose iron sucrose;
- Increased physician awareness of high-dose iron replacement;
- Repeat treatment for chronic or recurrent iron deficiency.
No public source provides a separately audited Monoferric revenue series. Pharmacosmos reports corporate activities and product information but does not provide a public, SEC-style product-level income statement.
Medium-term outlook
Revenue growth is likely to depend more on market share and net price than on expansion of the overall intravenous iron category. The product faces pricing pressure from generic iron sucrose and potentially from generic or authorized-generic competitors in other intravenous iron categories.
A favorable scenario includes:
- Sustained preference for high-dose replacement;
- Payer recognition of lower administration burden;
- Increased concern over ferric carboxymaltose-associated hypophosphatemia;
- Additional evidence in heart failure and other specialty populations;
- Continued U.S. formulary expansion.
A downside scenario includes:
- Rebates required to match Injectafer and Feraheme;
- Hospital conversion to lower-cost iron sucrose;
- Narrow reimbursement policies;
- Limited use outside the FDA-approved U.S. indications;
- Loss of important patent or regulatory protection without sufficient brand loyalty.
What patents protect ferric derisomaltose?
Protection for ferric derisomaltose is based on iron-carbohydrate composition, manufacturing, formulation, and use claims. The relevant patent estate is more complex than a single compound patent because ferric derisomaltose is a pharmaceutical complex rather than a conventional small molecule with one defined active structure.
Pharmacosmos has historically held patents covering iron carbohydrate complexes and related compositions. Public patent records include the following representative U.S. patent families associated with iron-carbohydrate technology:
| Patent |
General subject matter |
Commercial relevance |
| U.S. Patent No. 7,612,079 |
Iron-carbohydrate complexes and related pharmaceutical compositions |
Core technology family associated with high-dose intravenous iron |
| Related continuation and foreign families |
Composition, preparation, and medical-use claims |
Geographic and claim-scope protection varies by jurisdiction |
Patent expiration analysis must be conducted at the individual patent and claim level. A composition patent’s expiration does not automatically eliminate manufacturing, formulation, method-of-use, or regulatory barriers.
What is the Orange Book status of Monoferric?
Monoferric is an FDA-approved prescription drug. Orange Book-listed patent protection, regulatory exclusivity, and the timing of abbreviated new drug applications determine the U.S. generic-entry pathway.
The commercial assessment should distinguish:
- Patents listed for the reference product;
- Regulatory exclusivity under the Federal Food, Drug, and Cosmetic Act;
- Patent-term adjustment or extension;
- Paragraph IV certifications;
- Litigation filed within the statutory 45-day period;
- Settlement terms affecting a potential launch date.
The 2020 approval date means the product’s five-year new chemical entity exclusivity period would have ended in January 2025, assuming the relevant FDA exclusivity designation was granted. That period prevents submission of an ANDA for the same active ingredient during the protected window, subject to statutory exceptions. Patent protection may continue separately.
When does ferric derisomaltose lose exclusivity?
Ferric derisomaltose does not have a single universal exclusivity-loss date. The timing depends on three separate protections:
| Protection |
Effect |
| FDA regulatory exclusivity |
Restricts certain abbreviated or 505(b)(2) submissions for a defined period |
| Listed patents |
Can delay approval or launch of an ANDA after a Paragraph IV challenge |
| Manufacturing and formulation know-how |
May raise the practical barrier even after formal patent expiry |
The U.S. five-year new chemical entity period associated with a 2020 approval would generally run through January 2025. A patent-controlled launch date could be later or earlier depending on the patent family, litigation outcome, settlement, and the status of any listed claims.
In Europe, exclusivity depends on the marketing authorization, data exclusivity, market exclusivity, supplementary protection certificates, and national patent rights. Patent expiration dates therefore vary by country.
Which companies are challenging ferric derisomaltose?
The principal competitive threat is expected from generic injectable iron manufacturers and established pharmaceutical companies with intravenous iron portfolios. Potential competitors include manufacturers of generic iron sucrose, ferumoxytol, ferric carboxymaltose, and iron dextran.
Publicly available information does not establish a single definitive, market-wide list of ANDA applicants or Paragraph IV challengers for Monoferric. FDA approval of a generic injectable iron also requires adequate chemistry, manufacturing, controls, and product-comparability evidence. The development burden can be higher than for a conventional oral tablet because iron-carbohydrate complexes require characterization of particle size, iron release, carbohydrate structure, and pharmacologic equivalence.
What generic entry risks exist for Monoferric?
The generic-entry risk is moderate in the near term and increases over time.
Regulatory barriers
A developer must demonstrate that the proposed product is equivalent to the reference product under the applicable FDA pathway. For complex iron-carbohydrate products, analytical similarity and quality characterization can be more demanding than for simple small molecules.
Manufacturing barriers
Commercial production requires control of:
- Iron-carbohydrate complex formation;
- Molecular-weight distribution;
- Iron release characteristics;
- Free iron and labile iron;
- Sterility and particulate matter;
- Batch-to-batch consistency.
These requirements can limit the number of credible generic manufacturers.
Commercial barriers
Even after approval, a generic must obtain hospital and payer contracts. The entrant must demonstrate a meaningful price advantage or persuade institutions to replace a branded product with a complex injectable alternative.
Launch scenarios
| Scenario |
Expected impact |
| No approved generic before patent barriers clear |
Monoferric retains branded pricing and formulary leverage |
| First generic launches with limited contracting |
Moderate price erosion; continued brand use in selected accounts |
| Multiple approved generics |
Significant rebate and net-price pressure |
| Authorized generic or settlement launch |
Earlier controlled erosion with potential preservation of market access |
What patent litigation and settlement issues affect ferric derisomaltose?
Patent litigation risk centers on whether a generic applicant submits a Paragraph IV certification against a listed patent. If the patent holder files suit within 45 days, FDA approval can be stayed for up to 30 months, subject to statutory exceptions and court developments.
Publicly reported litigation involving Monoferric has not produced a broadly recognized market-wide settlement framework comparable to major blockbuster drug cases. The absence of a widely disclosed settlement does not eliminate risk. Patent disputes can arise over composition claims, manufacturing processes, pharmaceutical formulations, and methods of treating iron deficiency.
Settlement terms, if reached, could include:
- A fixed generic entry date;
- A license limited to certain indications;
- A royalty or supply arrangement;
- A no-contest provision;
- Acceleration rights if a patent is invalidated;
- Restrictions on authorized-generic competition.
How strong is the ferric derisomaltose patent estate?
The estate has moderate technical strength but less conventional durability than a classic small-molecule composition patent.
Its strengths are:
- Complex-product manufacturing know-how;
- Potentially differentiated composition and process claims;
- High analytical burden for follow-on products;
- Multiple clinical uses across jurisdictions;
- Manufacturing scale and quality-control requirements.
Its weaknesses are:
- Limited ability to rely on one long-lived molecular patent;
- Potential claim-construction disputes;
- Increasing generic expertise in intravenous iron;
- Substitution pressure from established low-cost products;
- Product-level revenue concentration in a limited therapeutic class.
Commercial durability is therefore likely to depend on manufacturing quality, clinical evidence, hospital contracts, and payer economics as much as on patent duration.
What is the geographic market for ferric derisomaltose?
Ferric derisomaltose has a broader international commercial history than its U.S. launch date suggests.
| Region |
Brand or product position |
| United States |
Monoferric, marketed by Pharmacosmos |
| European Union and United Kingdom |
Monofer, subject to national approvals and reimbursement |
| Canada and selected international markets |
Local brand, distributor, or licensing arrangements may apply |
| Emerging markets |
Access depends on registration, tender systems, and local manufacturing requirements |
Europe is important because intravenous iron is widely used in chronic kidney disease, heart failure, gastroenterology, and women’s health. National reimbursement decisions can produce significant differences in volume and price.
What licensing deals affect ferric derisomaltose?
Pharmacosmos is the originator and principal rights holder. Commercialization outside core Pharmacosmos markets can involve local distributors, licensees, or regional marketing partners.
Public information does not establish a single global licensing transaction that determines the product’s entire revenue trajectory. The relevant commercial structure is market-specific and may include direct sales in some countries and partner-led distribution in others.
Licensing can improve geographic penetration but reduce the originator’s net revenue per unit. It also creates dependency on local registration, tender access, reimbursement, and partner execution.
What is the FDA regulatory and competitive outlook?
The FDA-approved U.S. indication gives Monoferric a defensible base in adult iron deficiency anemia and non-dialysis CKD. Broader clinical use is possible where supported by evidence, but off-label use does not provide the same commercial protection as a labeled indication.
The U.S. competitive landscape is defined by:
- Injectafer’s commercial scale;
- Feraheme’s established CKD and iron-deficiency use;
- Venofer’s generic pricing;
- Hospital preference for fewer infusions;
- Payer control over site of care and reimbursement;
- Concern about hypophosphatemia with ferric carboxymaltose.
Biosimilar risk is not applicable in the conventional sense. Ferric derisomaltose is a non-biologic complex drug, so competitors would generally pursue generic, hybrid, or other abbreviated pathways rather than the biosimilar pathway used for biologic medicines.
What revenue exposure does Pharmacosmos have to ferric derisomaltose?
Pharmacosmos has meaningful exposure to ferric derisomaltose because Monoferric and Monofer are central products in its iron-deficiency portfolio. The company’s private ownership limits external visibility into product-level revenue, operating margins, and regional sales concentration.
Financial sensitivity is highest in the United States, where:
- Branded intravenous iron pricing is material;
- Hospital and payer contracts influence net price;
- Competition with Injectafer is direct;
- The product is still building market share relative to older iron products;
- Any generic approval could alter price and volume assumptions.
The product’s profitability is likely stronger in branded markets with high-dose reimbursement and weaker in tender-driven markets where iron sucrose and other generics dominate.
Key Takeaways
- Ferric derisomaltose is marketed as Monoferric in the United States and Monofer in Europe.
- Pharmacosmos is the originator and principal commercial holder.
- The FDA approved Monoferric in January 2020 for adults with iron deficiency anemia and non-dialysis-dependent CKD.
- Its central commercial advantage is large-dose intravenous replacement, often in one infusion.
- The leading branded competitor is ferric carboxymaltose, while iron sucrose is the major low-cost alternative.
- Hypophosphatemia data can support switching from ferric carboxymaltose, but contracting and acquisition price remain decisive.
- The five-year U.S. regulatory exclusivity period associated with the 2020 approval would generally have ended in January 2025.
- Patent protection depends on multiple composition, process, formulation, and use claims rather than one simple molecular patent.
- Generic-entry risk is constrained by analytical characterization and manufacturing complexity, but it rises as regulatory and patent barriers weaken.
- Pharmacosmos does not publicly disclose a separately audited global Monoferric or Monofer revenue figure.
FAQs
Is ferric derisomaltose the same as iron dextran?
No. Ferric derisomaltose and low-molecular-weight iron dextran are different iron-carbohydrate complexes with distinct labeling, dosing, manufacturing characteristics, and clinical data.
Does ferric derisomaltose cause hypophosphatemia?
It can, but comparative studies generally report a lower risk of hypophosphatemia than ferric carboxymaltose. Monitoring remains appropriate for patients at elevated risk.
Is Monoferric a biologic or biosimilar?
No. Monoferric is a non-biologic intravenous iron complex. Follow-on products would generally use generic or hybrid regulatory pathways rather than biosimilar approval.
Can ferric derisomaltose be used in dialysis patients?
Clinical use may occur in dialysis settings, but the U.S. Monoferric label specifically identifies non-dialysis-dependent CKD. Dialysis protocols and reimbursement rules determine whether it is commercially adopted.
What is the main risk to ferric derisomaltose sales?
The main risk is loss of net pricing or volume to ferric carboxymaltose, ferumoxytol, iron sucrose, and future generic entrants. Hospital formulary decisions and payer contracts are more important to near-term sales than prescription demand alone.
References
-
American Regent, Inc. (2023). Injectafer (ferric carboxymaltose injection) prescribing information. U.S. Food and Drug Administration.
-
Pharmacosmos Therapeutics Inc. (2020). Monoferric (ferric derisomaltose injection) prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2020, January 14). FDA approves Monoferric for iron deficiency anemia. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Patent No. 7,612,079. (2009). Iron carbohydrate complexes. United States Patent and Trademark Office.
-
Wolf, M., Chertow, G. M., Macdougall, I. C., Kaper, R., Krop, J., & Strauss, W. (2020). Randomized trial of intravenous iron-induced hypophosphatemia. Journal of Clinical Investigation, 130(12), 6361-6370. https://doi.org/10.1172/JCI140825
-
World Health Organization. (2020). WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. World Health Organization.
